Comments
McBleezy8 t1_ir6w0gv wrote
The study itself for those interested Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry
[deleted] t1_ir8g1x1 wrote
[removed]
[deleted] t1_ir6ugyq wrote
[removed]
[deleted] t1_ir6w590 wrote
[removed]
[deleted] t1_ir6yeph wrote
[removed]
[deleted] t1_ir79pnw wrote
[removed]
AutoModerator t1_ir6lun7 wrote
Welcome to r/science! This is a heavily moderated subreddit in order to keep the discussion on science. However, we recognize that many people want to discuss how they feel the research relates to their own personal lives, so to give people a space to do that, personal anecdotes are now allowed as responses to this comment. Any anecdotal comments elsewhere in the discussion will continue to be removed and our normal comment rules still apply to other comments.
I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.
[deleted] t1_ir6n5u6 wrote
[removed]
[deleted] t1_ir7c8h1 wrote
[removed]
[deleted] t1_ir908sl wrote
[removed]
[deleted] t1_ira6a71 wrote
[removed]
[deleted] t1_ir8k5jt wrote
[removed]
[deleted] t1_ir7qjqy wrote
[removed]
Doomenor t1_ir78pxn wrote
“Results: Seventy-four patients with ASD were included in the analysis. The mean age of participants was 32.7 (±11.6) years. There were significant improvements in general health-related quality of life and sleep as assessed by the EQ-5D-5L, SQS and GAD-7 at 1 and 3 months, with sustained changes in EQ-5D-5L and SQS at 6 months (p < 0.010). There were 180 (243.2%) adverse events reported by 14 (18.9%) participants. If present, adverse events were commonly mild (n = 58; 78.4%) or moderate (n = 81; 109.5%), rather than severe (n = 41; 55.4%).
Conclusion: This study demonstrated an associated improvement in general health-related quality of life, and anxiety- and sleep-specific symptoms following initiation of treatment with CBMPs in patients with ASD. These findings, while promising, are limited by the confines of the study which lacks a control arm and is subject to attrition bias. Therefore, further evaluation is required with randomised controlled trials.”